Efficacy and safety of a 72‐h infusion of prostacyclin (1 ng/kg/min) in mechanically ventilated patients with pulmonary infection and endotheliopathy—protocol for the multicenter randomized, placebo‐controlled, blinded, investigator‐initiated COMBAT ‐ ARF trial
Acta Anaesthesiologica Scandinavica · 2025
DOI: 10.1111/aas.14565 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Acta Anaesthesiologica Scandinavica, 2025. Verfasst von Peter Søe-Jensen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesia and Intensive Care, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark. Hauptthemen laut MEDLINE: COVID-19, Epoprostenol, Respiration, Artificial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Fonden, Alfred Benzon Foundation.
Abstract (Originalsprache)
Background
Acute respiratory failure (ARF) is common in critically ill patients, and 50% of patients in intensive care units require mechanical ventilation [3, 4]. The COVID‐19 pandemic revealed that COVID‐19 infection induced ARF caused by damage to the microvascular pulmonary endothelium. In a randomized clinical trial, mechanically ventilated COVID‐19 patients with severe endotheliopathy, as defined by soluble thrombomodulin (sTM) ≥ 4 ng/mL, were randomized to evaluate the effect of a 72‐h infusion of low‐dose prostacyclin 1 ng/kg/min or placebo. Twenty‐eight‐day mortality was 21.9% versus 43.6% in the prostacyclin and the placebo groups, respectively (RR 0.50; CI 0.24 to 0.96 p = .06). The aim of the current trial is to investigate if this beneficial effect and safety of prostacyclin also are present in any patient with suspected pulmonary infection requiring mechanical ventilation and concomitant severe endotheliopathy. Materials and Methods This is a multi‐center, randomized, blinded, clinical investigator‐initiated phase 3 trial in mechanically ventilated patients with suspected pulmonary infection and severe endotheliopathy, as defined by sTM ≥4 ng/mL. Patients are randomized 1:1 to a 72‐h infusion of low‐dose prostacyclin (iloprost) 1 ng/kg/min or placebo (an equal volume of saline). Four‐hundred fifty patients will be included. The primary endpoint is 28‐day all‐cause mortality. Secondary endpoints include 90‐day mortality, days alive without vasopressor, mechanical ventilation, and renal replacement therapy in the ICU within 28 and 90 days, and the number of serious adverse reactions or serious adverse events within the first 7 days.
Discussion
This trial will investigate the efficacy and safety of prostacyclin vs. placebo for 72‐hours in mechanically ventilated patients with any suspected pulmonary infection and severe endotheliopathy, as defined by sTM ≥4 ng/mL. Trial endpoints focus on the potential effect of prostacyclin to reduce 28‐day all‐cause mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesia and Intensive Care, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.
- Department of Anaesthesia and Intensive Care, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Anaesthesia and Intensive Care, Copenhagen University Hospital-North Zealand, Hilleroed, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Anaesthesia and Intensive Care, Zealand University Hospital-Køge, Køge, Denmark.
- Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Pär I Johansson
Förderung
- Novo Nordisk Fonden
- Alfred Benzon Foundation
Zitieren
APA
Søe-Jensen, P., Clausen, N. E., Bestle, M. H., Andersen, L. P. K., Lange, T., Johansson, P. I., & Stensballe, J. (2025). Efficacy and safety of a 72‐h infusion of prostacyclin (1 ng/kg/min) in mechanically ventilated patients with pulmonary infection and endotheliopathy—protocol for the multicenter randomized, placebo‐controlled, blinded, investigator‐initiated COMBAT ‐ ARF trial. Acta Anaesthesiologica Scandinavica. https://doi.org/10.1111/aas.14565
Vancouver
Søe-Jensen P, Clausen NE, Bestle MH, Andersen LPK, Lange T, Johansson PI, et al. Efficacy and safety of a 72‐h infusion of prostacyclin (1 ng/kg/min) in mechanically ventilated patients with pulmonary infection and endotheliopathy—protocol for the multicenter randomized, placebo‐controlled, blinded, investigator‐initiated COMBAT ‐ ARF trial. Acta Anaesthesiologica Scandinavica. 2025. doi:10.1111/aas.14565
BibTeX
@article{SeJensen2025,
author = {Søe-Jensen, Peter and Clausen, Niels E and Bestle, Morten H and Andersen, Lars P K and Lange, Theis and Johansson, Pär I and Stensballe, Jakob},
title = {Efficacy and safety of a 72‐h infusion of prostacyclin (1 ng/kg/min) in mechanically ventilated patients with pulmonary infection and endotheliopathy—protocol for the multicenter randomized, placebo‐controlled, blinded, investigator‐initiated COMBAT ‐ ARF trial},
journal = {Acta Anaesthesiologica Scandinavica},
year = {2025},
doi = {10.1111/aas.14565}
}
EUVIMED